Search | Clinical Trials Finder

Recognized from query: Pfizer Phase 3 trials. Matching terms were moved into the structured fields above when recognized.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 718 matching trials from the live ClinicalTrials.gov search.

Filters: "Pfizer Phase 3 trials" Clear all

Conditions: Follicular Lymphoma
Interventions: PF-05280586, MabThera®; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 91
States / cities: Anaheim, California • Corona, California • Downey, California + 62 more

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 31
States / cities: Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more

Conditions: Hematologic Neoplasms
Interventions: Piperacillin/Tazobactam (Tazocin); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 31
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 25 more

Conditions: Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions: Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,068 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 77
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 50 more

Conditions: Maxillary Sinusitis
Interventions: azithromycin SR (Zithromax; compound: CP-62,993), placebo, levofloxacin; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 59
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 37 more

Conditions: COVID-19 SARS-CoV-2 Infection
Interventions: ibuzatrelvir, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 2,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 90
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 66 more

Conditions: Venous Thromboembolism, Brain Tumors
Interventions: dalteparin; Drug
Lead sponsor: Ontario Clinical Oncology Group (OCOG); Other
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 3
States / cities: Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah

Conditions: Bipolar Disorder
Interventions: Placebo, Geodon (Ziprasidone); Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 43
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 39 more

Conditions: Schizophrenia
Interventions: bifeprunox, risperidone; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 66
States / cities: Little Rock, Arkansas • Anaheim, California • Boynton Beach, California + 52 more

Conditions: COVID-19, SARS-COV-2 Infection
Interventions: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain); Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 12 Years and older
Enrollment: 774 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 19
States / cities: Walnut Creek, California • Milford, Connecticut • Washington D.C., District of Columbia + 13 more

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2%, Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Fountain Valley, California • Fremont, California • Colorado Springs, Colorado + 20 more

Conditions: Influenza
Interventions: CAIV-T; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: COVID-19, SARS-CoV-2
Interventions: Azithromycin, Placebos; Drug
Lead sponsor: Thomas M. Lietman; Other
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ankylosing Spondylitis
Interventions: Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 28
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 22 more

Conditions: Fibromyalgia
Interventions: Pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 93
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 78 more

Conditions: Transient Insomnia
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Glendale, California • San Diego, California • Overland Park, Kansas

Conditions: Mycoses, HIV Infections
Interventions: Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Ulcerative Colitis
Interventions: tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 19
States / cities: Los Angeles, California • San Francisco, California • Farmington, Connecticut + 10 more

Conditions: Juvenile Idiopathic Arthritis
Interventions: Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 43
States / cities: Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 23 more

Conditions: Osteoarthritis
Interventions: tanezumab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 226
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 148 more

Conditions: Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 48
States / cities: Huntsville, Alabama • Union Grove, Alabama • Fresno, California + 40 more

Conditions: Transient Insomnia
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 2,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 23
States / cities: Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 17 more

Conditions: Hemophilia A
Interventions: ReFacto AF, B-Domain deleted Recombinant Factor VIII, BDDrFVIII; Genetic
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 21
States / cities: Phoenix, Arizona • Sacramento, California • San Diego, California + 18 more

Conditions: Osteoarthritis, Arthritis, Pain
Interventions: Placebo IV, Placebo SC, Tanezumab SC, Tanezumab IV; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 91
States / cities: Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 64 more

Search by objective public record fields.

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

Azithromycin for COVID-19 Treatment in Outpatients Nationwide

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

An Open-Label Trial of Pregabalin in Patients With Fibromyalgia

A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Extension Study Of Tanezumab In Osteoarthritis

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study